ASP Isotopes Inc. (NASDAQ:ASPI) Shares Sold by GSA Capital Partners LLP

GSA Capital Partners LLP decreased its position in shares of ASP Isotopes Inc. (NASDAQ:ASPI) by 29.6% during the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 569,578 shares of the company’s stock after selling 239,133 shares during the period. ASP Isotopes accounts for approximately 0.2% of GSA Capital Partners LLP’s portfolio, making the stock its 20th largest holding. GSA Capital Partners LLP’s holdings in ASP Isotopes were worth $2,671,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of ASPI. BNP Paribas Financial Markets purchased a new position in shares of ASP Isotopes in the 4th quarter valued at $34,000. SBI Securities Co. Ltd. grew its holdings in ASP Isotopes by 84.8% during the 1st quarter. SBI Securities Co. Ltd. now owns 9,370 shares of the company’s stock valued at $44,000 after purchasing an additional 4,299 shares in the last quarter. Russell Investments Group Ltd. grew its holdings in ASP Isotopes by 56.3% during the 4th quarter. Russell Investments Group Ltd. now owns 10,221 shares of the company’s stock valued at $46,000 after purchasing an additional 3,682 shares in the last quarter. LPL Financial LLC acquired a new stake in ASP Isotopes during the 4th quarter valued at $54,000. Finally, Covestor Ltd acquired a new stake in ASP Isotopes during the 4th quarter valued at $54,000. Hedge funds and other institutional investors own 16.80% of the company’s stock.

ASP Isotopes Trading Down 3.5%

NASDAQ ASPI opened at $10.10 on Tuesday. The company has a debt-to-equity ratio of 0.80, a quick ratio of 7.17 and a current ratio of 7.21. The company has a 50-day simple moving average of $8.14 and a 200-day simple moving average of $6.26. The firm has a market capitalization of $847.39 million, a PE ratio of -16.56 and a beta of 3.35. ASP Isotopes Inc. has a one year low of $1.86 and a one year high of $10.82.

Analyst Ratings Changes

Separately, Canaccord Genuity Group raised their price objective on shares of ASP Isotopes from $8.50 to $11.00 and gave the stock a “buy” rating in a report on Wednesday, May 21st.

ASP Isotopes Profile

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235.